Abstract
For the pharmacological treatment of frequency, urgency and/or urge incontinence due to bladder overactivity, anticholinergics have been used as first-choice drugs. However, these drugs can exert severe side effects (accommodation paralysis, constipation, tachycardia, dry mouth and blurred vision) and some patients are refractory to their actions. Thus there is a need for new drug therapies with novel mechanisms of action. β-Adrenoceptors are found in the body of the bladder, where they mediate relaxation of the detrusor muscle. It has been reported that β3-adrenoceptor subtypes are predominantly present in the smooth muscles of bladder and urethra in the pig and human. Recently, β3-adrenoceptors have been reported to predominantly mediate relaxation of the bladder smooth muscle. However, the relaxant effects of β3-adrenoceptor agonists are half of those of (±)isoproterenol, a non-selective - adrenoceptor agonist, and the antagonist affinity of β3-adrenoceptor antagonists varies according to the drugs tested. It has also been suggested that both β2-, and β3-adrenoceptors are involved in relaxation of the human bladder, but the involvement of the β3-adrenoceptor may be greater than that of β2-adrenoceptor. Another possibility is that other -adrenoceptors, possibly β4-adrenoceptor and/or atypical β-adrenoceptors, may coexist and play a functional role in mediating the relaxation of the bladder.
Keywords: β-adrenoceptor, subtype, bladder, smooth muscle, overactive bladder
Current Drug Therapy
Title: Which β-Adrenoceptor Subtypes are Important in the Treatment of Overactive Bladder?
Volume: 2 Issue: 1
Author(s): Tomonori Yamanishi, Takao Kamai, Ryuji Sakakibara, Tomoyuki Uchiyama, Tatsuya Yamamoto, Takashi Ito and Ken-ichiro Yoshida
Affiliation:
Keywords: β-adrenoceptor, subtype, bladder, smooth muscle, overactive bladder
Abstract: For the pharmacological treatment of frequency, urgency and/or urge incontinence due to bladder overactivity, anticholinergics have been used as first-choice drugs. However, these drugs can exert severe side effects (accommodation paralysis, constipation, tachycardia, dry mouth and blurred vision) and some patients are refractory to their actions. Thus there is a need for new drug therapies with novel mechanisms of action. β-Adrenoceptors are found in the body of the bladder, where they mediate relaxation of the detrusor muscle. It has been reported that β3-adrenoceptor subtypes are predominantly present in the smooth muscles of bladder and urethra in the pig and human. Recently, β3-adrenoceptors have been reported to predominantly mediate relaxation of the bladder smooth muscle. However, the relaxant effects of β3-adrenoceptor agonists are half of those of (±)isoproterenol, a non-selective - adrenoceptor agonist, and the antagonist affinity of β3-adrenoceptor antagonists varies according to the drugs tested. It has also been suggested that both β2-, and β3-adrenoceptors are involved in relaxation of the human bladder, but the involvement of the β3-adrenoceptor may be greater than that of β2-adrenoceptor. Another possibility is that other -adrenoceptors, possibly β4-adrenoceptor and/or atypical β-adrenoceptors, may coexist and play a functional role in mediating the relaxation of the bladder.
Export Options
About this article
Cite this article as:
Yamanishi Tomonori, Kamai Takao, Sakakibara Ryuji, Uchiyama Tomoyuki, Yamamoto Tatsuya, Ito Takashi and Yoshida Ken-ichiro, Which β-Adrenoceptor Subtypes are Important in the Treatment of Overactive Bladder?, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422329
DOI https://dx.doi.org/10.2174/157488507779422329 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Management of Inflammatory Bowel Disease Using Stem Cell Therapy
Current Stem Cell Research & Therapy Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Molecular Basis of Gastrointestinal Chemical Senses)
Current Pharmaceutical Design Lipid Oxidation Products in the Pathogenesis of Inflammation-related Gut Diseases
Current Medicinal Chemistry Viruses and Oral Cancer: Crossreactivity as a Potential Link
Anti-Cancer Agents in Medicinal Chemistry Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Laminin and Collagen IV: Two Polypeptides as Marker of Dystocic Labor
Current Protein & Peptide Science Computational Strategies for the Development of Novel Small Molecule Rheumatoid Arthritis Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Roles for G-Quadruplexes in Mitochondria
Current Medicinal Chemistry The Endocannabinoid System May Modulate Sleep Disorders in Aging
Current Neuropharmacology Regulation of Nociceptive Transmission at the Periphery Via TRPA1-TRPV1 Interactions
Current Pharmaceutical Biotechnology Potential Approaches for Beta Cell Imaging with PET and SPECT
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Hypercoagulability in Sickle Cell Disease and Beta-Thalassemia
Current Molecular Medicine Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica
Current Neurovascular Research Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design